[go: up one dir, main page]

MC2324A1 - Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone - Google Patents

Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone

Info

Publication number
MC2324A1
MC2324A1 MC912324A MC2324A MC2324A1 MC 2324 A1 MC2324 A1 MC 2324A1 MC 912324 A MC912324 A MC 912324A MC 2324 A MC2324 A MC 2324A MC 2324 A1 MC2324 A1 MC 2324A1
Authority
MC
Monaco
Prior art keywords
interactions
inhibition
cell adhesive
adhesive proteins
carbon hydrates
Prior art date
Application number
MC912324A
Other languages
English (en)
Inventor
Seed Brian Mm
Gerd Walz
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of MC2324A1 publication Critical patent/MC2324A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MC912324A 1990-11-23 1991-11-18 Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone MC2324A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61831490A 1990-11-23 1990-11-23

Publications (1)

Publication Number Publication Date
MC2324A1 true MC2324A1 (fr) 1994-01-18

Family

ID=24477202

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912324A MC2324A1 (fr) 1990-11-23 1991-11-18 Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone

Country Status (16)

Country Link
US (5) US5858983A (fr)
EP (1) EP0640129A1 (fr)
JP (2) JPH06504619A (fr)
AU (1) AU656934B2 (fr)
BR (1) BR9106995A (fr)
CA (1) CA2097617A1 (fr)
CZ (1) CZ96893A3 (fr)
FI (1) FI932336L (fr)
HU (1) HUT64476A (fr)
IE (1) IE914075A1 (fr)
IL (1) IL100094A0 (fr)
MC (1) MC2324A1 (fr)
NO (1) NO931864L (fr)
NZ (1) NZ240646A (fr)
PT (1) PT99582A (fr)
WO (1) WO1992009293A1 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387884B1 (en) * 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) * 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
WO1992009293A1 (fr) * 1990-11-23 1992-06-11 The General Hospital Corporation Inhibition des interactions entre des proteines d'adhesion cellulaire et des hydrates de carbone
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
EP0521692A3 (en) * 1991-07-02 1993-02-03 The Biomembrane Institute Inhibition of tumor cell metastasis potential and invasiveness by chemically-defined oligosaccharides, their derivatives, mimetics and antibodies directed to them
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
ES2169724T3 (es) * 1992-10-02 2002-07-16 Alberta Res Council Propiedades antiinflamatorias, tolerogenicas e inmunoestimulantes de peptidos que enlazan carbohidratos.
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
AU753310B2 (en) * 1998-05-20 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Novel method for gene cloning
ES2571230T3 (es) * 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20030096281A1 (en) * 2001-09-14 2003-05-22 Ganesh Venkataraman Methods of making glycomolecules with enhanced activities and uses thereof
US20030086929A1 (en) * 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase
EP1500400A4 (fr) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Medicament contenant une composition anticorps
EP1534725A2 (fr) 2002-05-16 2005-06-01 Glycomimetics, Inc. Composes et procedes d'inhibition des fonctions induites par les selectines
CA2490703A1 (fr) * 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions et methodes permettant le diagnostic et le traitement d'etats pathologiques impliquant l'angiogenese
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US20060021071A1 (en) * 2003-10-09 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Cell in which genome is modified
US7691810B2 (en) * 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
CA2542121A1 (fr) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Cellule modifiee par genome neutralisee jusqu'a obtention d'un systeme exempt de serum
EP1763533B1 (fr) * 2003-11-19 2008-01-09 GlycoMimetics, Inc. Antagoniste specifique pour e-selectines et p-selectines
CA2546784A1 (fr) * 2003-11-19 2005-06-16 Glycomimetics, Inc. Antagonistes glycomimetiques pour les selectines de type e et p
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
WO2006127906A1 (fr) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Composes heterobifonctionnels pour l’inhibition de la selectine
ES2375979T3 (es) * 2005-08-09 2012-03-07 Glycomimetics, Inc. Inhibidores glicomiméticos de la lectina pa-il, lectina pa-iil o ambas lectinas de pseudomonas.
EP2264043B1 (fr) 2005-09-02 2017-11-08 GlycoMimetics, Inc. Inhibiteurs de pan-selectine heterobifonctionnels
AU2006312148B2 (en) * 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
US20110014270A1 (en) * 2006-03-27 2011-01-20 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury and related conditions
AU2007235413B2 (en) * 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007143052A1 (fr) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides et thiodigalactosides en tant qu'inhibiteurs de la lectine pa-il de pseudomonas
EP2074132B1 (fr) 2006-10-12 2013-05-15 GlycoMimetics, Inc. Replacements glycomimétiques pour des hexoses et des n-acétylhexosamines
EP2117561A1 (fr) * 2007-02-09 2009-11-18 GlycoMimetics, Inc. Procédés d'utilisation de glycomimétiques avec des remplacements d'hexoses et d'hexosamines d'acétyle n
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2009126556A1 (fr) 2008-04-08 2009-10-15 Glycomimetics, Inc. Inhibiteur de pan-sélectine avec activité pharmacocinétique améliorée
MX2010011598A (es) * 2008-04-22 2010-12-15 Univ Rockefeller Metodos para identificar compuestos anti-inflamatorios.
AU2009257536B2 (en) * 2008-06-13 2015-07-02 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
JP5726171B2 (ja) * 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
CN101921336B (zh) * 2009-06-11 2013-02-27 北京华大蛋白质研发中心有限公司 一种抗人α1酸性糖蛋白的单克隆抗体及其制备方法
AU2011237442A1 (en) 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
CN103080130B (zh) 2010-05-27 2016-08-17 默沙东公司 制备具有改进特性的抗体的方法
WO2012037034A1 (fr) 2010-09-14 2012-03-22 Glycomimetics, Inc. Antagonistes de l'e-sélectine
CN103782168B (zh) 2011-03-12 2016-03-16 动量制药公司 在糖蛋白产品中包含n-乙酰己糖胺的n-聚醣
EP2714732A4 (fr) 2011-05-25 2014-12-10 Merck Sharp & Dohme PROCÉDÉ DE PRÉPARATION DE POLYPEPTIDES CONTENANT Fc À PROPRIÉTÉS AMÉLIORÉES
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
EP2856159A4 (fr) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc Méthodes associées au denosumab
SI2928476T1 (en) 2012-12-07 2018-06-29 Glycomimetics, Inc. COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
EP3058084A4 (fr) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
CA3009836A1 (fr) 2016-01-22 2017-07-27 Glycomimetics, Inc. Inhibiteurs glycomimetiques des lectines pa-il et pa-iil
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
WO2019108750A1 (fr) 2017-11-30 2019-06-06 Glycomimetics, Inc. Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
CN111867601A (zh) 2018-03-05 2020-10-30 糖模拟物有限公司 用于治疗急性髓系白血病及相关病症的方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2021148983A1 (fr) 2020-01-24 2021-07-29 Pfizer Inc. Anticorps anti-e-sélectine, compositions et procédés d'utilisation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4184917A (en) * 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
DE2621908A1 (de) * 1975-05-26 1976-12-09 Sandoz Ag Neues diagnostikum fuer maligne tumore
JPS53136586A (en) * 1977-05-02 1978-11-29 Ajinomoto Co Inc Preparation of llglutamic acidd*c* semialdehyde
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60123494A (ja) * 1983-12-08 1985-07-02 Rikagaku Kenkyusho シアル酸含有オリゴ糖およびその製造法
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
JPS6283898A (ja) * 1985-10-09 1987-04-17 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺腺癌特異的単クロ−ン性抗体
US4851511A (en) * 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
EP0323802A3 (fr) * 1987-12-24 1989-07-26 Sandoz Ag Anticorps monoclonaux contre, et antigène de la surface cellulaire de cancer du poumon
EP0357767B1 (fr) * 1988-03-11 1995-05-24 The Biomembrane Institute Anticorps monoclonaux et mise au point d'un vaccin developpe contre des antigenes cancereux humains par immunisation avec de la mucine animale et humaine et avec des conjugues porteurs de glucides synthetiques
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
FR2654876B1 (fr) * 1989-11-23 1993-11-12 Commissariat A Energie Atomique Dispositif de charge de moyens d'accumulation d'energie electrique, muni de moyens permettant de maitriser cette charge.
JPH05501359A (ja) * 1990-04-27 1993-03-18 バイオジェン，インコーポレイテッド 付着分子発現に関与するフコシルトランスフェラーゼ
US5211936A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a cite of inflammation utilizing elam-1 ligands site
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5143712A (en) * 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
WO1992009293A1 (fr) * 1990-11-23 1992-06-11 The General Hospital Corporation Inhibition des interactions entre des proteines d'adhesion cellulaire et des hydrates de carbone
CA2108786A1 (fr) * 1991-04-19 1992-10-20 John L. Magnani Compositions et methodes de liaison endotheliale
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates

Also Published As

Publication number Publication date
US5801044A (en) 1998-09-01
AU9061891A (en) 1992-06-25
US5723583A (en) 1998-03-03
EP0640129A1 (fr) 1995-03-01
CZ96893A3 (en) 1993-12-15
US6156881A (en) 2000-12-05
US6613746B1 (en) 2003-09-02
WO1992009293A1 (fr) 1992-06-11
NZ240646A (en) 1994-01-26
CA2097617A1 (fr) 1992-05-23
EP0640129A4 (fr) 1994-07-05
NO931864D0 (no) 1993-05-21
HU9301510D0 (en) 1993-10-28
AU656934B2 (en) 1995-02-23
NO931864L (no) 1993-07-21
HUT64476A (en) 1994-01-28
FI932336A0 (fi) 1993-05-21
JPH06504619A (ja) 1994-05-26
IE914075A1 (en) 1992-06-03
US5858983A (en) 1999-01-12
PT99582A (pt) 1992-10-30
IL100094A0 (en) 1992-08-18
JP2000325092A (ja) 2000-11-28
BR9106995A (pt) 1993-08-24
FI932336L (fi) 1993-05-21

Similar Documents

Publication Publication Date Title
MC2324A1 (fr) Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone
FR2617712B1 (fr) Substance inhibitrice du developpement cellulaire dite dolastatine 10
AU588220B2 (en) Improved expression vector and use thereof
BR8803135A (pt) Composicao consolidavel e material refratario
DE69505257D1 (de) Elektrochemische oxydation von materialien
EP0828431A4 (fr) Substituts de creme contenant des hydrates de carbone/proteines
TR23107A (tr) Sert pvc'den mamuel doekuem parcalarinin yapistinlmasina mahsus madde
DE69333921D1 (de) "enhancer" sequenz zur modulation der expression in epithelialzellen
FR2611142B1 (fr) Poche d'ostomie
AU8094682A (en) Bacillus thuringiensis mutant and insecticide based thereon
FR2577141B1 (fr) Protection des hydrocarbures contre l'action de microorganismes
AU7284787A (en) Copy and material holder
NO170811C (no) Oxydasjons- og varmemotstandsdyktig sammensatt gjenstand og legeringsmateriale
AU8073391A (en) Clip providing improved storage and handling of flexible bags
DK227985D0 (da) Kloning og karakterisering af det humane interleukin 1 gen
DE69324812D1 (de) Zellaktivator des eingeweidetraktes
EP0082738A3 (en) Salts of amino organic peroxides and uses thereof
AU8193391A (en) Photobioreactors and closed ecological life support systems and artificial lungs containing the same
EP0230669A3 (en) Rubber composition and hose and diaphragm made therefrom
BR8901182A (pt) Suspensao aquosa estavel e utilizacao desta suspensao
IL90184A0 (en) Functionalized peptidyl aminodiols and-triols
IT1175825B (it) Dispersione adesiva reattiva e procedimento d'impiego
FR2615447B1 (fr) Feuille composite pour le revetement etanche d'elements de construction et procedes pour sa realisation
FR2736585B3 (fr) Reliure d'art en matiere dure et rigide
DK278388A (da) Beta-(fluormethylen)-5-hydroxytryptophan og derivater heraf samt anvendelsen af disse forbindelser